118 related articles for article (PubMed ID: 33220402)
1. Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
Basiri A; Zhang W; Garrison J
Bioorg Med Chem Lett; 2021 Jan; 31():127697. PubMed ID: 33220402
[TBL] [Abstract][Full Text] [Related]
2. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
Gu Y; Patterson AV; Atwell GJ; Chernikova SB; Brown JM; Thompson LH; Wilson WR
Mol Cancer Ther; 2009 Jun; 8(6):1714-23. PubMed ID: 19509245
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
4. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs.
Parker LL; Lacy SM; Farrugia LJ; Evans C; Robins DJ; O'Hare CC; Hartley JA; Jaffar M; Stratford IJ
J Med Chem; 2004 Nov; 47(23):5683-9. PubMed ID: 15509167
[TBL] [Abstract][Full Text] [Related]
5. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of mustard derivatives of thymine.
Hadj-Bouazza A; Teste K; Colombeau L; Chaleix V; Zerrouki R; Kraemer M; Sainte Catherine O
Nucleosides Nucleotides Nucleic Acids; 2008 May; 27(5):439-48. PubMed ID: 18569783
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
Tercel M; Wilson WR; Anderson RF; Denny WA
J Med Chem; 1996 Mar; 39(5):1084-94. PubMed ID: 8676343
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
Singh RK; Kumar S; Prasad DN; Bhardwaj TR
Eur J Med Chem; 2018 May; 151():401-433. PubMed ID: 29649739
[TBL] [Abstract][Full Text] [Related]
10. Benzoyl and cinnamoyl nitrogen mustard derivatives of benzoheterocyclic analogues of the tallimustine: synthesis and antitumour activity.
Baraldi PG; Romagnoli R; Giovanna Pavani M; del Carmen Nunez M; Bingham JP; Hartley JA
Bioorg Med Chem; 2002 May; 10(5):1611-8. PubMed ID: 11886822
[TBL] [Abstract][Full Text] [Related]
11. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.
Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ
J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358
[TBL] [Abstract][Full Text] [Related]
12. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards.
Ware DC; Palmer BD; Wilson WR; Denny WA
J Med Chem; 1993 Jun; 36(13):1839-46. PubMed ID: 8515422
[TBL] [Abstract][Full Text] [Related]
14. New nitrogen mustards structurally related to (L)-carnitine.
Faissat L; Martin K; Chavis C; Montéro JL; Lucas M
Bioorg Med Chem; 2003 Feb; 11(3):325-34. PubMed ID: 12517428
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
Su TL; Lin YW; Chou TC; Zhang X; Bacherikov VA; Chen CH; Liu LF; Tsai TJ
J Med Chem; 2006 Jun; 49(12):3710-8. PubMed ID: 16759114
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status.
Rachid Z; Brahimi F; Domarkas J; Jean-Claude BJ
Bioorg Med Chem Lett; 2005 Feb; 15(4):1135-8. PubMed ID: 15686928
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen Mustards as Alkylating Agents: A Review on Chemistry, Mechanism of Action and Current USFDA Status of Drugs.
More GS; Thomas AB; Chitlange SS; Nanda RK; Gajbhiye RL
Anticancer Agents Med Chem; 2019; 19(9):1080-1102. PubMed ID: 30834842
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure-activity relationship and biological evaluation of novel nitrogen mustard sophoridinic acid derivatives as potential anticancer agents.
Li DD; Dai LL; Zhang N; Tao ZW
Bioorg Med Chem Lett; 2015 Oct; 25(19):4092-6. PubMed ID: 26299348
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
[TBL] [Abstract][Full Text] [Related]
20. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
